Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2005
10/20/2005US20050233983 Treatment of rumen acidosis with alpha-amylase inhibitors
10/20/2005US20050233974 Treating infectious diseases using ice inhibitors
10/20/2005US20050233955 Stimulation of nerve cell regeneration
10/20/2005US20050233947 Combinations of chromium or vanadium with antidiabetics
10/20/2005US20050233946 Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
10/20/2005US20050233944 Arginine compositions for coordinate modification of multiple cardiovascular risk factors
10/20/2005US20050233943 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
10/20/2005US20050233941 Pin coated assay
10/20/2005US20050233402 Heparinase III HLGAG fragments and uses thereof
10/20/2005US20050233396 an assay method of infecting cultured cells with vaccinia virus;co-transfecting the cells with plasmids of DNA encoding the I7L protease enzyme such that both the substrate protein and enzyme are expressed; then measuring cleaved I7L protease
10/20/2005US20050233371 CNG2B: a novel human cyclic nucleotide-gated ion channel
10/20/2005US20050233361 PPARdelta assay
10/20/2005US20050233359 Isolated nucleic acid molecule encoding a neurotrophic growth factor
10/20/2005US20050233341 Using single nucleotide polymorphism in fucose-1-phosphate guanylyltransferase (FPGT) and cyclin dependent kinase kinesin genes as diagnostic indicators of cell proliferative disorders; antitumor agents; ribozymes and tumor treatment; RNA interference
10/20/2005US20050233010 mood-stabilizing lithium citrate or lithium carbonate with other psychoactive drug; antidepressant, anxiolytic agent; psychological, bipolar disorder, schizophrenia; synergistic mixture; time release; combination reduces suidical tendencies
10/20/2005US20050233001 Particles of megestrol, megestrol acetate, and surface stabilizer; endometriosis, dysmenorrhea, hirsutism, uterine bleeding, neoplastic diseases, appetite enhancement, contraception
10/20/2005US20050232993 Dosage form containing promethazine and another drug
10/20/2005US20050232986 Dosage form containing promethazine and another drug
10/20/2005US20050232952 Self emulsifying drug delivery systems for poorly soluble drugs
10/20/2005US20050232925 Protease activity of thrombin inhibits angiogenesis
10/20/2005US20050232923 Methods and compositions for treating MCP-1 related pathologies
10/20/2005US20050232916 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor
10/20/2005US20050232915 Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer
10/20/2005US20050232908 Novel use of the extract of processed ginseng and saponin isolated therefrom
10/20/2005US20050232902 Injectable bioartificial tissue matrix
10/20/2005US20050232901 Materials and methods for treating or preventing oxalate-related disease
10/20/2005US20050232895 Anti-viral pharmaceutical compositions
10/20/2005US20050232891 Methods of treating skin with diphosphonate derivatives
10/20/2005US20050232874 Compound and method of treatment for fungal pathologies of the oral cavity
10/20/2005US20050232872 Compositions and methods for enhancing receptor-mediated cellular internalization
10/20/2005US20050232870 Method of treatment of dopamine-related dysfunction
10/20/2005US20050232868 In situ administering into nasal cavities; mixture of flow control agents and deactivating compound
10/20/2005US20050232862 Combination therapy for the treatment of estrogen-sensitive drugs
10/20/2005US20050231646 Circuit for processing video signal including information such as caption
10/20/2005DE10393805T5 Pharmazeutische Formulierungen, die ß-2-Adrenorezeptor-Agonisten und Xantine enthalten Included Pharmaceutical formulations beta-2-adrenoreceptor agonists and Xantine
10/20/2005CA2829943A1 Ion binding compositions
10/20/2005CA2806465A1 Ion binding polymers and uses thereof
10/20/2005CA2563316A1 Pten inhibitors
10/20/2005CA2562399A1 Diphenyl - indol-2-on compounds and their use in the treatment of cancer
10/20/2005CA2562231A1 Active substance combination of a carbinol compound and an opioid
10/20/2005CA2562219A1 Active substance combination comprising a carbinol combined to at least an nsaid
10/20/2005CA2561958A1 Composition and method for inhibiting platelet aggregation
10/20/2005CA2561954A1 Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
10/20/2005CA2561952A1 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
10/20/2005CA2561947A1 Preventives/remedies for cancer
10/20/2005CA2560941A1 Compositions as adjuvants to improve immune responses to vaccines and methods of use
10/20/2005CA2560727A1 Sequential sprm/progestin treatment
10/20/2005CA2560725A1 Systems and methods for providing a stem cell bank
10/20/2005CA2560416A1 Angiogenesis-affecting compounds and methods of use thereof
10/20/2005CA2557848A1 Ion binding compositions
10/19/2005EP1586900A2 Methods for identifying combinations of entities as therapeutics
10/19/2005EP1586580A2 Process for the purification of daptomycin
10/19/2005EP1586574A1 Medicaments containing betamimetic drugs and a novel anticholinesterase drug
10/19/2005EP1586336A1 Compositions containing copper salts and soy products
10/19/2005EP1586333A2 Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
10/19/2005EP1586332A1 Combined use of carnosinase inhibitor with l-carnosines and composition
10/19/2005EP1586329A1 Botulinum toxin pharmaceutical compositions
10/19/2005EP1586322A2 Compositions for inhibition of anglogenesis
10/19/2005EP1586321A1 New use of glutamate antagonists for the treatment of cancer
10/19/2005EP1585956A2 Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
10/19/2005EP1585771A1 Complexes of protein crystals and ionic polymers
10/19/2005EP1585532A2 Topical anti-infective formulations
10/19/2005EP1585528A1 Use of sphingomyelin and lyso-sphingomyelin as absorption enhancers
10/19/2005EP1585527A1 Compositions and methods for combination antiviral therapy
10/19/2005EP1585524A2 The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus
10/19/2005EP1585520A1 Therapeutic formulations for the treatment of beta-amyloid related diseases
10/19/2005EP1585512A1 Compositions and methods for improving the condition of patients suffering from copd and other diseases
10/19/2005EP1585508A2 Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels
10/19/2005EP1585497A1 Mastitis treatment
10/19/2005EP1461045A4 Glucosamine organic acid adducts
10/19/2005EP1438333A4 Anti-fusion assay
10/19/2005EP1414446B1 Pramipexol as an anticonvulsive agent
10/19/2005EP1339438B1 Preventing transplant rejection in the eye
10/19/2005EP1307245B1 Pharmaceutical form comprising a cell regulating factor and/or a cell proliferation promoter
10/19/2005EP1216059B1 Composition for ivf
10/19/2005EP1200095B1 Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances
10/19/2005EP1185712B8 New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
10/19/2005EP1173217B1 Enhanced delivery of nucleic acid-based drugs
10/19/2005EP1165055B1 Pharmaceutical composition containing estradiol or ethinylestradiol and an extrusion additive
10/19/2005EP1137946B1 Use of vascular endothelial growth factor (vegf)
10/19/2005EP1109570B1 Modulation of memory effector t-cells with a cd2 binding agent
10/19/2005EP1100541B1 Hydrogel for the therapeutic treatment of aneurysms
10/19/2005EP1047471B1 Systems for local delivery of an agent
10/19/2005EP0831891B1 Oxidant scavengers
10/19/2005EP0814774B1 Reduction of adhesions using controlled delivery of active oxygen inhibitors
10/19/2005CN1685064A Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
10/19/2005CN1685055A Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma
10/19/2005CN1684975A Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
10/19/2005CN1684737A Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
10/19/2005CN1684708A Anti-NGF antibodies for the treatment of various disorders
10/19/2005CN1684701A Ophthalmologic irrigation solutions and method
10/19/2005CN1684696A Oral and dental composition
10/19/2005CN1684693A Boronic acid polyvalent salts for treating thrombosis
10/19/2005CN1684689A Glaucoma-treating agent consisting of RHo kinase inhibitor and prostaglandin
10/19/2005CN1684683A Potent inhibitor of HCV serine protease
10/19/2005CN1684677A Composition containing arachidonic acid or the combination of docosahexenoic acid therewith for enhancing cognitive abilities
10/19/2005CN1684674A Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
10/19/2005CN1684673A Electrospun amorphous pharmaceutical compositions
10/19/2005CN1684667A Storage stable tablets of fosinopril sodium
10/19/2005CN1684662A Cleansing composition containing antifungal agent and antibacterial agent
1 ... 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 ... 1151